Prevalence of SARS-CoV-2 among high-risk populations in Lomé (Togo) in 2020

PLoS One. 2020 Nov 9;15(11):e0242124. doi: 10.1371/journal.pone.0242124. eCollection 2020.

Abstract

Background: In December 2019, the COVID-19 outbreak began in China and quickly spread throughout the world and was reclassified as a pandemic in March 2020. The first case of COVID-19 was declared in Togo on March 5. Two months later, few data were available to describe the circulation of the new coronavirus in the country.

Objective: This survey aimed to estimate the prevalence of SARS-CoV-2 in high-risk populations in Lomé.

Materials and methods: From April 23, 2020, to May 8, 2020, we recruited a sample of participants from five sectors: health care, air transport, police, road transport and informal. We collected oropharyngeal swabs for direct detection through real-time reverse transcription polymerase chain reaction (rRT-PCR) and blood for antibody detection by serological tests. The overall prevalence (current and past) of infection was defined by positivity for both tests.

Results: A total of 955 participants with a median age of 36 (IQR 32-43) were included, and 71.6% (n = 684) were men. Approximately 22.1% (n = 212) were from the air transport sector, 20.5% (n = 196) were from the police sector, and 38.7% (n = 370) were from the health sector. Seven participants (0.7%, 95% CI: 0.3-1.6%) had a positive rRT-PCR test result at the time of recruitment, and nine (0.9%, 95% CI: 0.4-1.8%) were seropositive for IgM or IgG against SARS-CoV-2. We found an overall prevalence of 1.6% (n = 15), 95% CI: 0.9-2.6%.

Conclusion: The prevalence of SARS-CoV-2 infection among high-risk populations in Lomé was relatively low and could be explained by the various measures taken by the Togolese government. Therefore, we recommend targeted screening.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Viral / blood
  • Betacoronavirus / genetics
  • Betacoronavirus / isolation & purification
  • COVID-19
  • Coronavirus Infections / epidemiology
  • Coronavirus Infections / pathology*
  • Coronavirus Infections / virology
  • Cross-Sectional Studies
  • Female
  • Humans
  • Immunoassay
  • Male
  • Middle Aged
  • Pandemics
  • Pneumonia, Viral / epidemiology
  • Pneumonia, Viral / pathology*
  • Pneumonia, Viral / virology
  • Prevalence
  • RNA, Viral / genetics
  • RNA, Viral / metabolism
  • Real-Time Polymerase Chain Reaction
  • Risk Factors
  • SARS-CoV-2
  • Togo / epidemiology

Substances

  • Antibodies, Viral
  • RNA, Viral

Grants and funding

This work was supported by the Government of the Republic of Togo. In addition, Dr Rodion KONU was supported by the Agence Nationale de Recherche sur le sida et les hépatites virales (ANRS)’ in France for his training in Masters of Public Health degree at the ‘Université de Bordeaux’ through the Françoise Barre Sinoussi Fellowship 2019. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.